EMAN RESEARCH PUBLISHING | Journal | <p>Undertsanding cancer for non-technical pupils</p>
Angiogenesis biology and therapeutics
LETTERS   (Open Access)

Undertsanding cancer for non-technical pupils

Norliyana Amran

+ Author Affiliations

Journal of Angiotherapy 1(1) 039-040 https://doi.org/10.25163/angiotherapy.11000951108100517

Submitted: 11 September 2016  Revised: 15 February 2017  Published: 10 May 2017 

Cancer develops following a number of genetic mutations that cause functional alterations in oncogenes, tumor-suppressor genes and microRNA genes.

Abstract


Cancer is reported to have affected every fourth citizen of a developed country sometime during his or her lifetime. Approximately 400 new incidents emerge per 100,000 people annually (Parkin et al., 2005). In 2008, it was estimated that there were 12.7 million cancer cases and 7.6 million deaths (within 5 years of diagnosis) globally (Ferley et al.,2010). Further, this number will continue to increase year by year. But the question remains, what is cancer? There are many definitions of cancer and the easiest way to explain it is uncontrollable proliferation of cell. Cancer develops following a number of genetic mutations that cause functional alterations in oncogenes, tumor-suppressor genes and microRNA genes. It can affect any part of the body by means of uncontrolled and abnormal cell development (Vanhoecke et al., 2005).

Keywords: Cancer, Deaths, Tumor, Oncogenes

References


Browder T, Butterfield CE, Kraling BM, Marshall B, O’Reilly MS, Folkman J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60, 1878–1886

Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers C. and Parkin, D.M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917.

Folkman, J. (1971). Tumor angiogenesis. Therapeutic implications. N Engl J Med, 285, 1182–1186

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature,  348(6301), 555–557.

Kasibhatla, S. and Tseng, B. (2003). Why Target Apoptosis in Cancer Treatment? Molecular Cancer Therapeutics, 2, 573–580.

Kintzios, S.E. & Barberaki, M.G. (2004). Plants that fight cancer, CRC Press, Boca Raton.

Lopes, F., Rocha, A., Pirraco, A., Regasini, L., Silva, D., Bolzani, V., Azevedo, I., Carlos, I. and Soares, R. (2009). Anti-angiogenic effects of pterogynidine alkaloid isolated from Alchornea glandulosa. BMC Complementary and Alternative Medicine, 9(1), 1-11.

Naveen Kumar, D.R., Shikha, S., Cijo George, V., Suresh, P.K. and Ashok Kumar, R.  (2012).

Anticancer and anti-metastatic activities of Rheum emodi rhizome chloroform extracts. Asian Journal of Pharmaceutical and Clinical Research, 3, 189–194.

Narang, A.S. and Desai, D.S. (2009). Anticancer drug development. In Pharmaceutical Perspectives of Cancer Therapeutics, Springer: Berlin, German, pp. 49–92.

Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005). Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians, 55(2), 74-108.

Pesenti, E., Sola, F., Mongelli, N., Grandi, M. and Spreafico, F. (1992). Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. British Journal of Cancer, 66, 367–372.

Vanhoecke, B.W., Depypere, H.T., De Beyter, A., Sharma, S.K., Parmar, V.S., De Keukeleire, D. and Bracke, M.E., (2005). New anti-invasive compounds: Results from the Indo-Belgian screening program. Pure and Applied Chemistry, 77(1) 65-74.

Committee on Publication Ethics

Buy PDF
Full Text
Export Citation

View Dimensions


View Plumx



View Altmetric



0
Save
0
Citation
80
View
0
Share